Guglin, M., Hartlage, G., Reynolds, C., et al. (2009) Trastuzumab-induced cardiomyopathy: Not as benign as it looks? A retrospective study. Journal of Cardiac Failure, 15, 651-657.
has been cited by the following article:
TITLE: Radiation associated coronary occlusion: Overlooked as trastuzumab-induced cardiomyopathy
AUTHORS: Ugur Turk, Veysel Yavuz, Nurullah Cetin
KEYWORDS: Cardiomyopathy; Trastuzumab; Radiation
JOURNAL NAME: Open Journal of Internal Medicine, Vol.3 No.1, March 22, 2013
ABSTRACT: Trastuzumab is an agent used for receptor-positive breast cancer. Up to a third of patients treated with trastuzumab might develop cardiomyopathy. Many patients with breast cancer have taken pre- or co-administration of mediastinal radiotherapy. Both of treatment modalities have toxic effects on myocardium. It may result with diagnostic confusion between radiation-induced CAD (riCAD) and trastuzumab cardiomyopathy in the case with dilated cardiomyopathy. TTE may offer clues of differential diagnosis.